SCHEMBL16634233

SCHEMBL16634233

Cc1cc(Br)cnc1/C=C/C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 5/20 0.39
GAA P10253 2/20 0.39
P4HTM Q9NXG6 1/20 0.39
EIF2AK2 P19525 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 1/20 0.36
RAB9A P51151 2/20 0.36
BLM P54132 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
POLB P06746 2/20 0.33
AKR1C4 P17516 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
HPGD P15428 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16634234 1.00 KDM4E (0.39) KDM4EALDH1A1GAAP4HTMEIF2AK2
SCHEMBL16634171 0.80 MIF (0.39) KDM4EALDH1A1GAAP4HTMEIF2AK2
SCHEMBL16634172 0.80 MIF (0.39) KDM4EALDH1A1GAAP4HTMEIF2AK2
SCHEMBL16634241 0.80 KDM4E (0.48) KDM4EALDH1A1GAACSNK2A2CSNK2B
SCHEMBL16634242 0.80 KDM4E (0.48) KDM4EALDH1A1GAACSNK2A2CSNK2B
SCHEMBL15278739 0.79 AAK1 (0.41) ALDH1A1SMN1; SMN2RAB9ACYP3A4BCHE
Cyclopropane SCHEMBL11663526 0.78 P4HTM (0.47) KDM4EALDH1A1GAAP4HTMSMN1; SMN2
SCHEMBL16303855 0.77 S1PR1 (0.35) KDM4EALDH1A1SMN1; SMN2NPSR1MAPK1
SCHEMBL31613762 0.74 KCNJ1 (0.37) KDM4EALDH1A1SMN1; SMN2NPSR1MAPK1
SCHEMBL1912446 0.74 KCNJ1 (0.37) KDM4EALDH1A1SMN1; SMN2NPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2828243-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2018-10-17 EP disclosed
US-9499538-B2 Estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
US-20150105403-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS, INC. 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105403-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR2, ESRRG, GPER1 KDM4E 2785/4885ALDH1A1 1178/4885GAA 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.